These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 25018036)

  • 21. Molecular Subtypes and Gene Expression Signatures as Prognostic Features in Fully Resected Clear Cell Renal Cell Carcinoma: A Tailored Approach to Adjuvant Trials.
    Roussel E; Verbiest A; Kinget L; Boeckx B; Zucman-Rossi J; Couchy G; Caruso S; Job S; de Reyniès A; De Wever L; Baldewijns M; Van Poppel H; Joniau S; Lambrechts D; Albersen M; Beuselinck B
    Clin Genitourin Cancer; 2021 Dec; 19(6):e382-e394. PubMed ID: 34362692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A CpG-methylation-based assay to predict survival in clear cell renal cell carcinoma.
    Wei JH; Haddad A; Wu KJ; Zhao HW; Kapur P; Zhang ZL; Zhao LY; Chen ZH; Zhou YY; Zhou JC; Wang B; Yu YH; Cai MY; Xie D; Liao B; Li CX; Li PX; Wang ZR; Zhou FJ; Shi L; Liu QZ; Gao ZL; He DL; Chen W; Hsieh JT; Li QZ; Margulis V; Luo JH
    Nat Commun; 2015 Oct; 6():8699. PubMed ID: 26515236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting glycolysis with 2-deoxy-D-glucose sensitizes primary cell cultures of renal cell carcinoma to tyrosine kinase inhibitors.
    Simon AG; Esser LK; Ellinger J; Branchi V; Tolkach Y; Müller S; Ritter M; Kristiansen G; Muders MH; Mayr T; Toma MI
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2255-2265. PubMed ID: 32533404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integration of NRP1, RGS5, and FOXM1 expression, and tumour necrosis, as a postoperative prognostic classifier based on molecular subtypes of clear cell renal cell carcinoma.
    Yoshida T; Ohe C; Ikeda J; Atsumi N; Saito R; Taniguchi H; Ohsugi H; Sugi M; Tsuta K; Matsuda T; Kinoshita H
    J Pathol Clin Res; 2021 Nov; 7(6):590-603. PubMed ID: 34212534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma.
    Shinohara N; Abe T
    Int J Urol; 2015 Oct; 22(10):888-97. PubMed ID: 26147084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management.
    Maruschke M; Reuter D; Koczan D; Hakenberg OW; Thiesen HJ
    BJU Int; 2011 Jul; 108(2 Pt 2):E29-35. PubMed ID: 21435154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival Prediction of Clear Cell Renal Cell Carcinoma Based on Gene Expression Similarity to the Proximal Tubule of the Nephron.
    Büttner F; Winter S; Rausch S; Reustle A; Kruck S; Junker K; Stenzl A; Agaimy A; Hartmann A; Bedke J; Schwab M; Schaeffeler E
    Eur Urol; 2015 Dec; 68(6):1016-20. PubMed ID: 26072688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
    Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
    J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High cytoplasmic expression of p27(Kip1) is associated with a worse cancer-specific survival in clear cell renal cell carcinoma.
    Kruck S; Merseburger AS; Hennenlotter J; Scharpf M; Eyrich C; Amend B; Sievert KD; Stenzl A; Bedke J
    BJU Int; 2012 May; 109(10):1565-70. PubMed ID: 21981759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and validation of an immune prognostic classifier for clear cell renal cell carcinoma.
    Gu YY; Chen G; Lin P; Cheng JW; Huang ZG; Luo J; Zhai GQ; Wang YL; Yan HB; Li SH
    Cancer Biomark; 2020; 27(2):265-275. PubMed ID: 31929144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.
    Fisel P; Kruck S; Winter S; Bedke J; Hennenlotter J; Nies AT; Scharpf M; Fend F; Stenzl A; Schwab M; Schaeffeler E
    Clin Cancer Res; 2013 Sep; 19(18):5170-81. PubMed ID: 23881922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of Tyrosine Kinase Inhibitor
    Miyake H; Imai S; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
    Anticancer Res; 2017 Mar; 37(3):1523-1528. PubMed ID: 28314328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deep sequencing reveals microRNAs predictive of antiangiogenic drug response.
    García-Donas J; Beuselinck B; Inglada-Pérez L; Graña O; Schöffski P; Wozniak A; Bechter O; Apellániz-Ruiz M; Leandro-García LJ; Esteban E; Castellano DE; González Del Alba A; Climent MA; Hernando S; Arranz JA; Morente M; Pisano DG; Robledo M; Rodriguez-Antona C
    JCI Insight; 2016 Jul; 1(10):e86051. PubMed ID: 27699216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD31, EDNRB and TSPAN7 are promising prognostic markers in clear-cell renal cell carcinoma revealed by genome-wide expression analyses of primary tumors and metastases.
    Wuttig D; Zastrow S; Füssel S; Toma MI; Meinhardt M; Kalman K; Junker K; Sanjmyatav J; Boll K; Hackermüller J; Rolle A; Grimm MO; Wirth MP
    Int J Cancer; 2012 Sep; 131(5):E693-704. PubMed ID: 22213152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ontological analyses reveal clinically-significant clear cell renal cell carcinoma subtypes with convergent evolutionary trajectories into an aggressive type.
    Cai Q; Christie A; Rajaram S; Zhou Q; Araj E; Chintalapati S; Cadeddu J; Margulis V; Pedrosa I; Rakheja D; McKay RM; Brugarolas J; Kapur P
    EBioMedicine; 2020 Jan; 51():102526. PubMed ID: 31859241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
    Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
    Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. No Significant Correlation of Clinical Outcomes Between First- and Second-line Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma.
    Miyazaki A; Miyake H; Harada K; Fujisawa M
    Anticancer Res; 2015 May; 35(5):3067-73. PubMed ID: 25964597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs.
    Beuselinck B; Jean-Baptiste J; Couchy G; Job S; De Reynies A; Wolter P; Théodore C; Gravis G; Rousseau B; Albiges L; Joniau S; Verkarre V; Lerut E; Patard JJ; Schöffski P; Méjean A; Elaidi R; Oudard S; Zucman-Rossi J
    Br J Cancer; 2015 Nov; 113(9):1313-22. PubMed ID: 26528707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Involvement of the TNF-α Pathway in TKI Resistance and Suggestion of TNFR1 as a Predictive Biomarker for TKI Responsiveness in Clear Cell Renal Cell Carcinoma.
    Hwang HS; Park YY; Shin SJ; Go H; Park JM; Yoon SY; Lee JL; Cho YM
    J Korean Med Sci; 2020 Feb; 35(5):e31. PubMed ID: 32030920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transcriptome Sequencing (RNAseq) Enables Utilization of Formalin-Fixed, Paraffin-Embedded Biopsies with Clear Cell Renal Cell Carcinoma for Exploration of Disease Biology and Biomarker Development.
    Eikrem O; Beisland C; Hjelle K; Flatberg A; Scherer A; Landolt L; Skogstrand T; Leh S; Beisvag V; Marti HP
    PLoS One; 2016; 11(2):e0149743. PubMed ID: 26901863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.